1-3 of 3
Jessica Lowney
Close
Sort by
Journal Articles

Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Matthew S. Davids, MD, Benjamin L. Lampson, MD PhD, Svitlana Tyekucheva, PhD, Jennifer L. Crombie, MD, Samuel Ng, MD PhD, Austin I. Kim, MD, Matthew Weinstock, MD, Jessica Lowney, Samantha Pazienza, Josie Montegaard, NP, Victoria Patterson, BSN, RN, Caron A. Jacobson, MD, Ann S. LaCasce, MD MSc, Philippe Armand, MD PhD, Jon E. Arnason, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–21.
https://doi.org/10.1182/blood-2020-139864
Published: 2020
Journal Articles

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome

Jennifer L. Crombie, MD, Svitlana Tyekucheva, PhD, Zixu Wang, MS, Alexandra Savell, BS, Lisa Brennan, RN, BSN, Jessica Lowney, Karen Francoeur, RN, Josie Montegaard, NP, Austin I. Kim, MD, Jacob D. Soumerai, MD, Jon E. Arnason, MD, Allan Louie Cruz, MD, Sigrid Berg, MD, David C. Fisher, MD, Jennifer R Brown, MD PhD, Matthew S. Davids, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 46–47.
https://doi.org/10.1182/blood-2020-138811
Published: 2020
Journal Articles

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Benjamin L. Lampson, MD PhD, Svitlana Tyekucheva, PhD, Jennifer L. Crombie, MD, Austin I Kim, MD, Reid W Merryman, MD, Jessica Lowney, Josie Montegaard, NP, Victoria Patterson, RN, Caron A. Jacobson, MD, Eric D Jacobsen, MD, Ann S. LaCasce, MD MMSc, Jon E. Arnason, MD, Philippe Armand, MD PhD, David C. Fisher, MD, Jennifer R. Brown, MD PhD, Matthew S. Davids, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 32.
https://doi.org/10.1182/blood-2019-127506
Published: 2019